Fate Therapeutics, Inc. (FATE)
1.835
-0.02
(-0.81%)
USD |
NASDAQ |
Nov 06, 16:00
1.83
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics Research and Development Expense (Quarterly) : 21.54M for Sept. 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 21.54M |
| June 30, 2026 | 21.61M |
| March 31, 2026 | 21.78M |
| December 31, 2025 | 22.36M |
| September 30, 2025 | 22.61M |
| June 30, 2025 | 24.15M |
| March 31, 2025 | 25.80M |
| December 31, 2024 | 28.80M |
| September 30, 2024 | 30.04M |
| June 30, 2024 | 29.88M |
| March 31, 2024 | 27.32M |
| December 31, 2023 | 26.93M |
| September 30, 2023 | 29.54M |
| June 30, 2023 | 36.41M |
| March 31, 2023 | 61.44M |
| December 31, 2022 | 82.35M |
| September 30, 2022 | 76.62M |
| June 30, 2022 | 78.34M |
| March 31, 2022 | 69.38M |
| December 31, 2021 | 67.31M |
| September 30, 2021 | 51.61M |
| June 30, 2021 | 46.86M |
| March 31, 2021 | 43.89M |
| December 31, 2020 | 38.12M |
| September 30, 2020 | 29.92M |
| Date | Value |
|---|---|
| June 30, 2020 | 25.92M |
| March 31, 2020 | 28.57M |
| December 31, 2019 | 24.59M |
| September 30, 2019 | 22.62M |
| June 30, 2019 | 21.63M |
| March 31, 2019 | 17.29M |
| December 31, 2018 | 13.77M |
| September 30, 2018 | 13.33M |
| June 30, 2018 | 16.54M |
| March 31, 2018 | 11.19M |
| December 31, 2017 | 9.597M |
| September 30, 2017 | 8.334M |
| June 30, 2017 | 7.696M |
| March 31, 2017 | 7.76M |
| December 31, 2016 | 6.027M |
| September 30, 2016 | 6.586M |
| June 30, 2016 | 6.549M |
| March 31, 2016 | 6.409M |
| December 31, 2015 | 5.223M |
| September 30, 2015 | 4.816M |
| June 30, 2015 | 4.695M |
| March 31, 2015 | 4.568M |
| December 31, 2014 | 3.74M |
| September 30, 2014 | 3.965M |
| June 30, 2014 | 3.835M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| AVITA Medical, Inc. | 4.697M |
| Agenus, Inc. | 11.65M |
| Amgen, Inc. | 2.111B |
| Anika Therapeutics, Inc. | 7.895M |
| BioCryst Pharmaceuticals, Inc. | 57.97M |